Hamamatsu Photonics K.K. 6965
TSE · Japan · Elektronische Technologie
¥2.404,00+51,50 (+2,19 %)
Markt geschlossen· · JPY · Daten können verzögert sein
Kurse können verzögert sein und dienen nur zu Informationszwecken - keine Anlageberatung.
Markt geschlossen· · JPY · Daten können verzögert sein
Kurse können verzögert sein und dienen nur zu Informationszwecken - keine Anlageberatung.
Gesamtrendite inklusive Dividenden.
Wo der Kurs im Verhältnis zu seinen 50- und 200-Tage-Durchschnitten steht.
Makkler Fair Value, Finanzgesundheit, Analystenmeinung, Vergleichsunternehmen und MakklerAI.
Hamamatsu Photonics K.K has delivered a 52.7% return over the past year, which naturally puts the spotlight on whether that share price now lines up with the cash the business is expected to generate. For anyone watching Hamamatsu Photonics K.K after such a strong 12 month run, the key issue is how that market enthusiasm stacks up against the company’s underlying cash flows. The 52.7% gain over the last year puts recent buyers in a strong position. It also raises the question of whether the...
Accelerating momentum across major industry heavyweights—highlighted by Thermo Fisher Scientific’s Q2 2026 revenue beat, Hamamatsu Photonics’ launch of its dedicated Lasers & Fibers Business Unit, and BD’s $4.98 billion Q3 performance—is driving rapid adoption of optical diagnostic and imaging solutions worldwide. This report provides an in-depth analysis of key technological advancements, regional market shares, and competitive strategies across the global biophotonics sector. Biophotonics Mark
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global AI In Digital Pathology Market size & share revenue was valued at approximately USD 0.98 Billion in 2025 and is expected to reach USD 1.15 Billion in 2026 and is expected to reach around USD 5.14 Billion by 2035, at a CAGR of 18.02% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Leica Biosystems (Danahe
Aktuelle Schlagzeilen Dritter zu diesem Unternehmen, getrennt von Makklers eigener Redaktion und mit Verlinkung zum Herausgeber. Für die Richtigkeit ist der jeweilige Herausgeber verantwortlich.